2:1 for new genomic techniques
At the end of December, genetic engineering sceptics celebrated that the Council of Agriculture Ministers narrowly failed to reach a qualified...
Locate Bio Ltd raises £9.2m venture capital
Locate Bio said it will use the fresh money to finance a clinical study of LDGraft, a bone graft substitute containing a sustained-release...
TME Pharma gets FDA Fast Track for Glioblastoma
TME Pharma N.V. with research sites in France and Germany (listed at Euronext Growth Paris: ALTME) is developing novel therapies for treatment of...
PulseSight to disrupt AMD space
Aiming to address the pressing challenges of age-related macular diseases (AMD), including wet and dry AMD, along with geographic atrophy (GA),...
£26m for Cystic Fibrosis Drug Trial
With funding led by Panakes Partners and involvement from current investors, Enterprise Therapeutics Ltd. has received £26m (~€30.5m) for the Phase...
Genmab broadens ADC pipeline with $1.8bn acquisition of ProfoundBio
The acquisition will give Genmab access to ProfoundBio's portfolio of antibody-drug conjugates (ADCs), three of which are in clinical trials. The...
Bayer SE secures rights to in €310m deal
Under the licence deal, BridgeBio Pharma, Inc. will pass the commercialisation rights for the transthyretin stabiliser acoramidis in Europe where...